Edwards Lifesciences 

€63.06
-€2.4-3.67% Friday 16:30

統計

當日最高
63.16
當日最低
61.96
52週最高
-
52週最低
-
成交量
26
平均成交量
-
市值
-
市盈率
-
股息收益率
-
股息
-

即將到來

收益

30Jan預期
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Q3 2024
下一個
0.56
0.61
0.65
0.7
預期每股收益
0.562526
實際每股收益
N/A

人們還關注

此列表基於在 Stock Events 上關注 EWL.XETRA 的人的關注列表。這不是投資建議。

競爭者

這個列表是基於最近市場事件的分析。這不是投資建議。

關於

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Show more...
首席執行官
員工
15700
國家
DE
ISIN
US28176E1082
WKN
000936853

上市公司